Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 5
2006 3
2007 3
2008 1
2009 5
2010 4
2011 2
2012 8
2013 12
2014 8
2015 3
2016 5
2017 3
2018 8
2019 6
2020 7
2021 6
2022 8
2023 8
2024 11
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Inflammation induced by Bothrops asper venom.
Teixeira C, Cury Y, Moreira V, Picolo G, Chaves F. Teixeira C, et al. Toxicon. 2009 Jul;54(1):67-76. doi: 10.1016/j.toxicon.2009.03.019. Epub 2009 Mar 27. Toxicon. 2009. PMID: 19328821 Review.
Inflammation induced by Bothrops asper venom.
Teixeira C, Cury Y, Moreira V, Picolob G, Chaves F. Teixeira C, et al. Toxicon. 2009 Dec 1;54(7):988-97. doi: 10.1016/j.toxicon.2009.05.026. Toxicon. 2009. PMID: 19774698 Review.
Which Role Plays 2-Hydroxybutyric Acid on Insulin Resistance?
Sousa AP, Cunha DM, Franco C, Teixeira C, Gojon F, Baylina P, Fernandes R. Sousa AP, et al. Among authors: teixeira c. Metabolites. 2021 Dec 3;11(12):835. doi: 10.3390/metabo11120835. Metabolites. 2021. PMID: 34940595 Free PMC article. Review.
Membranous nephropathy associated with viral infection.
Nikolopoulou A, Teixeira C, Cook HT, Roufosse C, Cairns THD, Levy JB, Pusey CD, Griffith ME. Nikolopoulou A, et al. Among authors: teixeira c. Clin Kidney J. 2020 Apr 15;14(3):876-883. doi: 10.1093/ckj/sfaa026. eCollection 2021 Mar. Clin Kidney J. 2020. PMID: 33777370 Free PMC article.
106 results